Sun, Sep 11 at 12 PM CDT.
This is an invitation to the Annual General Meeting of the Cryonics Institute & the Immortalist Society.
The Cryonics Institute’s Annual General Meeting (AGM) will be held on Sunday, September 11th 2022 from 3:00pm to 6:30pm at the Infinity Hall & Sidebar 16,650 E. 14 Mile Rd, Fraser, MI 48,026 (USA). For more information visit www.infinityhallsidebar.com
Or call (586) 879‑6157.
This is not the first successful research on de-ageing cells. Earlier, Shinya Yamanaka, a Nobel prize-winning stem cell researcher, genetically reprogrammed the mouse skin cells and turned them into induced pluripotent stem cells, or iPSCs, back in 2006. These cells type had the potential to form any cell type in the body. Yamanaka’s method took 50 days and completely reprograms cells to the biological age of an embryo. Gill’s method only took 13 days.
In a statement, Gill said, “Our results represent a big step forward in our understanding of cell reprogramming. We have proved that cells can be rejuvenated without losing their function and that rejuvenation looks to restore some function to old cells.”
This is a 10-minute version with my picks on an hour-and-a-half interview on the longevity science made by Rhonda Patrick to Morgan Levine.
The link to the entire interview, which took place on April 12, 2022, is in the description of the video.
The interview took place on April 2022.
Morgan Levine is Assistant Professor at Yale University School of Medicine, author of TRUE AGE, and recently appointed Founding Principal Investigator at Altos Labs. She is heavily engaged in the field of the biology of aging.
Rhonda Patrick is CEO and Co-founder at FoundMyFitness. She is BS in Chemistry / Biochemistry form UC San Diego, and earned her PhD in Biomedical Science from The University of Tennessee Health Science Center.
Making positive impacts on human longevity — sonia arrison, author, analyst, investor, entrepreneur.
Sonia Arrison (https://soniaarrison.com/) is a best-selling author, analyst, entrepreneur, and investor.
Sonia is founder of 100 Plus Capital (https://100pluscap.com/ — Investing in companies positively impacting human longevity), Chair of the Alliance for Longevity Initiatives (https://a4li.org/ — The first and only 501©(4) nonprofit organization founded with the goal of creating social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years), co-founder of Unsugarcoat Media (acquired by Medium), and was an associate founder of Singularity University.
Sonia’s research focuses on exponentially growing technologies and their impact on society. Her book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity, and gained national best-seller status.
In addition to the Alliance for Longevity Initiatives, Sonia is a Board Member at the Thiel Foundation, Foresight Institute, and Woodland School. She is also a Senior Fellow at the Fraser Institute in Vancouver, British Columbia, and author of two previous books (Western Visions and Digital Dialog).
She gives a great analogy of slowing aging versus reversing aging, and I did not realize Yamanaka Factors were not so perfect in current use.
In this video Eleanor talks about the her view on Longevity Escape Velocity and reprogramming with Yamanaka factors and some of the issues around this technology.
Eleanor Sheekey graduated from Cambridge University with a masters degree in Biochemistry and is now studying for her PhD at the Cancer Research UK — Cambridge Institute. Eleanor is the person behind the Sheekey Science Show, a popular YouTube channel where she covers longevity and other topics with her deep knowledge of biochemistry.
The Sheekey Science Show can be found here.
https://www.youtube.com/c/TheSheekeyScienceShow.
Eleanor’s paper is here.
CARMAT, the developer of the world’s most advanced completely artificial heart has successfully raised €40.5 million in funding. The raise is set to finance the production of their Aeson artificial heart, which the company hopes will provide an alternative treatment option for people with heart failure – a condition affecting around 6.2 million adults in the US alone [1].
Longevity. Technology: Beating around 100,000 times per day, your heart works around the clock to keep your circulatory system ticking. The steady sound of your heartbeat is a comforting constant throughout your life. Forming the centre of the circulatory system, the heart continuously pumps blood around the body to deliver oxygen and nutrients to cells. Due to this constant work, our hearts can unfortunately wear out as we age, with cardiovascular diseases continuing to be the leading causes of death globally [2].
End-stage heart failure is a serious condition that occurs when the heart can no longer transport blood throughout the body effectively. It most often affects the left chamber of the heart, which pumps oxygen-rich blood around the body, leading to biventricular heart failure. Vital organs like the brain, liver and kidney fail to get enough oxygen and nutrients to function properly. With few treatment options, end-stage heart failure sometimes requires serious intervention like heart transplantation – considered the gold standard therapy. However, due to the global shortage in organ donors, this is not always possible and there is a gap for a therapeutic alternative that could have huge implications for longevity globally.
The SENS Research Foundation Board of Directors has a singular focus – to help the Foundation develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging. As the body responsible for ensuring the organization’s alignment with its mission, it is important our Board comprise leaders within the longevity field – visionaries dedicated to defeating the effects of aging permanently.
Many supporters have followed with interest our recent separation from our co-Founder Dr. Aubrey de Grey, and some have expressed concern regarding the possibility of our mission focus drifting off course. We remain firmly on-mission and continue to make real progress in our field, however, we acknowledge that we are the foundation we are today because of Dr. de Grey’s vision and leadership within the longevity movement. With this in mind, we have formally offered Dr. de Grey a Directorship within the Board of Directors.
His installment as a Director will be effective immediately upon the successful completion of the recommendations made by the accredited professional he has personally engaged, with a subsequent letter of recommendation to the Board of Directors supporting Dr. de Grey’s ability to fulfill the duties of Directorship. In this capacity, Dr. de Grey would lend his expertise to help steer the vision of the Foundation. Consistent with good governance and past practices, Dr. de Grey and the other members of the Board will approve the annual budget, review the annual audit, interview and hire executives, act as advocates for SRF, and largely ensure that the mission is being adhered to by the organization.
